A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
Dungan, K M
A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). [electronic resource] - Diabetes, obesity & metabolism May 2016 - 475-82 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1463-1326
10.1111/dom.12634 doi
Aged
Diabetes Mellitus, Type 2--blood
Double-Blind Method
Drug Administration Schedule
Drug Resistance
Drug Therapy, Combination--adverse effects
Female
Glucagon-Like Peptide-1 Receptor--metabolism
Glucagon-Like Peptides--administration & dosage
Glycated Hemoglobin--analysis
Humans
Hyperglycemia--prevention & control
Hypoglycemia--chemically induced
Hypoglycemic Agents--administration & dosage
Immunoglobulin Fc Fragments--administration & dosage
Injections, Subcutaneous
Intention to Treat Analysis
Male
Middle Aged
Patient Dropouts
Recombinant Fusion Proteins--administration & dosage
Sulfonylurea Compounds--adverse effects
Glucagon-Like Peptide-1 Receptor Agonists
A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). [electronic resource] - Diabetes, obesity & metabolism May 2016 - 475-82 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1463-1326
10.1111/dom.12634 doi
Aged
Diabetes Mellitus, Type 2--blood
Double-Blind Method
Drug Administration Schedule
Drug Resistance
Drug Therapy, Combination--adverse effects
Female
Glucagon-Like Peptide-1 Receptor--metabolism
Glucagon-Like Peptides--administration & dosage
Glycated Hemoglobin--analysis
Humans
Hyperglycemia--prevention & control
Hypoglycemia--chemically induced
Hypoglycemic Agents--administration & dosage
Immunoglobulin Fc Fragments--administration & dosage
Injections, Subcutaneous
Intention to Treat Analysis
Male
Middle Aged
Patient Dropouts
Recombinant Fusion Proteins--administration & dosage
Sulfonylurea Compounds--adverse effects
Glucagon-Like Peptide-1 Receptor Agonists